Aminex Therapeutics
Kirkland
About Aminex Therapeutics
Aminex Therapeutics, Inc. is a drug development company focused on the discovery, development, and commercialization of suppressor cell modulators (SCM), a new class of small molecule cancer immunotherapies that enable the immune system to attack cancer by regulating myeloid-derived suppressor cells. Aminex has extensively demonstrated, in animal trials, the potential of its lead drug, AMX-513, to be effective alone and to improve overall therapy when used in combination with other cancer treatments. Aminex's vision is to make significant treatment contributions for a wide range of cancers and to ease the rising costs of cancer therapy.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Estimated revenue: Less than $1M
- Total funding: $40.3M
- Last round: Series Unknown (Dec 2025)
- Website: aminextx.com
- Phone: (425) 286-4222
Industries & Categories
Biotechnology, Medical, Oncology, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/aminex-therapeutics-14717 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.